Ghost Tree Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Ghost Tree Capital’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$11.5M	Buy	350,000 +115,000	+49%	+$3.23M	3.48%	7
2024 Q2	$6.39M	Sell	235,000 -65,000	-22%	-$2.19M	2%	19
2024 Q1	$10.9M	Hold	300,000	–	–	3.02%	9
2023 Q4	$6.08M	Sell	300,000 -100,000	-25%	-$1.67M	1.99%	14
2023 Q3	$7.11M	Buy	400,000 +250,000	+167%	+$4.42M	2.34%	13
2023 Q2	$2.71M	Buy	150,000 +70,000	+88%	+$1.11M	0.89%	30
2023 Q1	$1.01M	Hold	80,000	–	–	0.3%	50
2022 Q4	$1.17M	Sell	80,000 -40,000	-33%	-$662K	0.5%	29
2022 Q3	$2.05M	Hold	120,000	–	–	0.58%	38
2022 Q2	$1.75M	Hold	120,000	–	–	0.91%	28
2022 Q1	$2.02M	Sell	120,000 -50,000	-29%	-$928K	0.44%	32
2021 Q4	$3.83M	Hold	170,000	–	–	1.37%	30
2021 Q3	$3.66M	Hold	170,000	–	–	1.07%	39
2021 Q2	$4.93M	Buy	+170,000	New	+$5.31M	1.35%	28

Other funds holding TARS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ghost Tree Capital's TARS Position: Q3 2024 in Review

Ghost Tree Capital increased its Tarsus Pharmaceuticals (TARS) stake by 49% in Q3 2024, buying an estimated $3.23M and bringing the position to 350,000 shares worth $11.5M. The position accounts for 3.48% of the portfolio, ranked #7.

Ghost Tree Capital first reported a position in TARS in Q2 2021 and has held it in 14 quarters since. 162 funds tracked by Wall St. Rank hold TARS as of Q3 2024.

Ghost Tree Capital held 350,000 shares of Tarsus Pharmaceuticals worth $11.5M as of Q3 2024.
Ghost Tree Capital bought 115,000 Tarsus Pharmaceuticals shares in Q3 2024, an estimated $3.23M.
Tarsus Pharmaceuticals made up 3.48% of Ghost Tree Capital's portfolio in Q3 2024, its #7 holding.
Ghost Tree Capital first reported a position in Tarsus Pharmaceuticals in Q2 2021 and has held it in 14 quarters since.
162 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.